• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PITAVASTATIN Drug Record

  • Summary
  • Interactions
  • Claims
  • PITAVASTATIN chembl:CHEMBL1201753 Approved

    Alternate Names:

    PITAVASTATIN
    ITAVASTATIN
    NK 104
    NK-104
    NKS104
    rxcui:861634
    chembl:CHEMBL1201753
    drugbank:08860
    pubchem.compound:5282452
    chemidplus:147511-69-1

    Drug Info:

    FDA Approval approved
    Drug Class small molecule
    Drug Indications anticholesterolaemic agent
    Year of Approval 2009
    Drug Class anticholesteremic agents
    (0 More Sources)

    Publications:

    Sai K et al., 2016, A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients., Drug Metab Pharmacokinet
    Oh ES et al., 2013, Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans., Drug Metab Pharmacokinet
    Wen J et al., 2010, OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers., J Clin Pharm Ther
    Hirano M et al., 2004, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans., J Pharmacol Exp Ther
    Hirano M et al., 2006, Drug-drug interaction between pitavastatin and various drugs via OATP1B1., Drug Metab Dispos
    Morgan et al., 2012, Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects., J. Cardiovasc. Pharmacol.
    Hoy SM, 2017, Pitavastatin: A Review in Hypercholesterolemia., Am J Cardiovasc Drugs
  • PITAVASTATIN   HMGCR

    Interaction Score: 3.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name pitavastatin , NK-104,Livalo

    PMIDs:
    22472908 28130659


    Sources:
    TdgClinicalTrial TEND

  • PITAVASTATIN   SLCO1B1

    Interaction Score: 1.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007012 20175818 15159445 16595711


    Sources:
    PharmGKB

  • PITAVASTATIN   HLA-DRB1

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27839692


    Sources:
    PharmGKB

  • PITAVASTATIN   ABCC2

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007012


    Sources:
    PharmGKB

  • TEND: PITAVASTATIN

    • Version: 01-August-2011

    Alternate Names:
    PITAVASTATIN Primary Drug Name

    Drug Info:
    Drug Class anticholesteremic agents
    Year of Approval 2009

    Publications:

  • TdgClinicalTrial: PITAVASTATIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications anticholesterolaemic agent
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • PharmGKB: pitavastatin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hirano M et al., 2004, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans., J Pharmacol Exp Ther
    Hirano M et al., 2006, Drug-drug interaction between pitavastatin and various drugs via OATP1B1., Drug Metab Dispos
    Wen J et al., 2010, OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers., J Clin Pharm Ther

  • ChemblDrugs: chembl:CHEMBL1201753

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21